Filing Flows › Comparisons › ENTX vs AIM
Entera Bio vs AIM ImmunoTech: ENTX and AIM compared
Entera Bio is the larger company: $42K of revenue in its latest quarter (Q1 2025) against $26K for AIM ImmunoTech (Q2 2026).
Where the money goes: ENTX and AIM
Entera Bio (ENTX) · Q1 2025
Entera Bio, Q1 2025: revenue $42K, net loss $2.6M, operating cash flow −$1.4M. The chart follows the revenue to costs, profit and cash.
AIM ImmunoTech (AIM) · Q2 2026
AIM ImmunoTech, Q2 2026: revenue $26K (+4% year over year), net loss $3.8M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
| Entera Bio (ENTX) | AIM ImmunoTech (AIM) | |
|---|---|---|
| Latest quarter | Q1 2025 | Q2 2026 |
| Revenue | $42K | $26K |
| Revenue growth, Y/Y | — | +4% |
| Operating margin | n/m | n/m |
| Net earnings | −$2.6M | −$3.8M |
| Operating cash flow | −$1.4M | −$4.6M |
Questions
Which is bigger, Entera Bio or AIM ImmunoTech?
Entera Bio is the larger company: $42K of revenue in its latest quarter (Q1 2025) against $26K for AIM ImmunoTech (Q2 2026).
More: Entera Bio earnings · how Entera Bio makes money · AIM ImmunoTech earnings · how AIM ImmunoTech makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 9, 2025; 10-Q filed Aug 7, 2026). Fiscal quarters can end on different dates. Not investment advice.